Recent Company News

• 08:59 AM ET Apr 11, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 07:33 AM ET Apr 28, 2025
  

  Halozyme issue press release on previously disclosed positive CHMP opinion for VYVGART (efgartigimod alfa) subcutaneous injection with ENHANZE for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ($60.49, 0.00)

• 01:03 AM ET Apr 28, 2025
  

  argenx issues press release on EMA's CHMP's recommending approval of Vyvgart to treat adults with progressive or relapsing CIDP ($614.76, 0.00)

• 10:48 AM ET Apr 25, 2025
  

  EU's CHMP adopted a positive opinion, recommending a change to the terms of the marketing authorisation for Vyvgart ($605.99, +5.48)

• 10:29 AM ET Apr 25, 2025
  

  EMA CHMP publishes summary of opinions for April meeting

• 08:45 PM ET Apr 11, 2025
  

  StreetAccount Sector Summary - Healthcare Weekly Recap

• 09:19 AM ET Apr 11, 2025
  

  StreetAccount Summary - US Pre-market trading update

• 08:20 AM ET Apr 11, 2025
  

  StreetAccount Summary - US Pre-market trading

• 05:48 PM ET Apr 10, 2025
  

  argenx announces FDA approval of VYVGART Hytrulo Prefilled syringe ($546.22, 0.00)